Reported results
- Net loss attributable to Arrowhead Pharmaceuticals, Inc. was $724,206 thousand for the year ended September 30, 2026.
- Revenue was $450,817 thousand for the year ended September 30, 2026.
- Total operating expenses were $1,157,988 thousand for the year ended September 30, 2026.
- Net loss per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted was $5.11 for the year ended September 30, 2026.
- Total cash resources (Cash, cash equivalents and restricted cash and Available-for-sale securities, at fair value) were $1,192,983 thousand as of September 30, 2026.
Guidance
- The Company is preparing for a potential U.S. launch of plozasiran in sHTG in the second quarter of 2027.
- The Company anticipates that the YOSEMITE clinical trial will be completed in mid-2027.
Notes
On November 9, 2026, the Board of Directors approved a change in the Company’s fiscal year end from September 30 to December 31, effective as of January 1, 2027.
Price and volatility reaction
The stock moved +1.3% on the print. No front-expiry chain was on file, so there is no straddle expected move.
| Measure | Value | Basis |
|---|---|---|
| Close before release | 47.15 | 2026-11-12 |
| Close after release | 47.78 | 2026-11-13 |
| Realised move | +1.3% | close to close |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
